相关实验视频

Updated: May 24, 2025

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

病理性和功能性粉样蛋白之间的相互作用:天堂或地狱中的匹配?

Daniel E Otzen¹, Samuel Peña-Díaz¹, Jeremias Widmann¹

¹Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Gustav Wieds Vej 14, 8000, Aarhus C, Denmark.

Molecular aspects of medicine

|March 2, 2025

概括

粉样蛋白,包括病理性人类粉样蛋白 (PaHA) 和功能性细菌粉样蛋白 (FuBA),在人体中相互作用,影响疾病的进展. 了解这些FuBA-PaHA相互作用是开发用于粉样蛋白疾病的新治疗策略的关键.

科学领域:

生物化学生物化学
微生物学微生物学
神经科学是一个神经科学.

背景情况:

粉样蛋白存在病理 (神经退行性疾病) 和功能 (细菌生物膜) 形式.
人体内含有病理性人类粉样蛋白 (PaHA),来自微生物群的功能性细菌粉样蛋白 (FuBA) 和饮食粉样蛋白.
粉样片段可以传播病态形式和交叉种子不相似的序列,在体内越来越多地涉及FuBA-PaHA相互作用.

研究的目的:

了解FuBA和PaHA之间的交叉对话的结构和生物信息基础.
研究FuBA-PaHA相互作用的机制,包括交叉刺激和抑制.
探索这些相互作用在神经退行性疾病的传播和发展中的作用.

主要方法:

利用了细菌粉样蛋白CsgA和FapC的原子层结构.
进行了体外和体内实验来研究FuBA-PaHA相互作用.
采用计算方法来分析序列和结构关系以及护送活动.

主要成果:

发现了FuBA和PaHA之间显著的交叉刺激和抑制,尽管序列同样性有限.
证明FuBA和PaHA可以通过肠-大脑轴相互作用,影响聚合和炎症.
表明微生物群的陪伴者可以识别和抑制FuBA和PaHA的生长.

结论:

FuBA和PaHA之间的异型相互作用是粉样蛋白现象的一个重要方面.
这些相互作用对神经退行性疾病的发展和传播有重大影响.
对FuBA-PaHA相互作用的进一步研究为了解和治疗粉样蛋白相关疾病提供了充满活力的前沿.

关键词:

聚合机制的聚合机制细菌的粉样蛋白是一种细菌的粉样蛋白.动脉是因为异型相互作用异型相互作用播种播种播种播种

更多相关视频

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Published on: November 30, 2018

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

相关概念视频

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...